Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Ashina M. Migraine. N Engl J Med. 2020;383(19):1866–76.
2. Messali A, Sanderson JC, Blumenfeld AM, Goadsby PJ, Buse DC, Varon SF, et al. Direct and indirect costs of chronic and episodic migraine in the United States: a web-based survey. Headache. 2016;56(2):306–22.
3. Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, et al. Migraine: epidemiology and systems of care. Lancet. 2021;397(10283):1485–95.
4. Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644–55.
5. Spanish Ministry of Health Positioning Report: Fremanezumab Therapeutics in Migraine Prophylaxis 2020. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT_11-2020-fremanezumab-Ajovy.pdf.